1. DANIEL KENT CASSAVAR, M.D.
21095 Rangeline Rd • Bowling Green, OH 43402 • (419) 872-7703• Daniel.cassavarmd@promedica.org
PHYSICIAN EXECUTIVE  CHIEF MEDICAL OFFICER
Interventional Cardiologist  Laboratory Management  Hospital Administration  Adjunct Clinical Professor
President and Chief Medical Officer with a history of a successful Interventional Cardiology practice,
management and retention of an 800-provider network and successful navigation between physician and
administrative duties. A Reputation for fairness in business and personal dealings, and an ongoing commitment to
focused delivery of accepted activities and tasks. I believe in the golden rule, being on time, and accepting
responsibility. I remain competent in performing all aspects of Interventional Cardiac care, as well as new-found
competencies in the areas listed below.
 Strategic Planning  Business Operations  Physician Recruitment
 Multi-Site Management  Contract Negotiations  Marketing / Expansion
 Process Improvement  Patient Satisfaction  Quality Care Standards
PROFESSIONAL EXPERIENCE
PROMEDICA, Toledo, Ohio
Comprehensive Northwest Ohio and Southeast Michigan health care network of 13 specialized hospitals, facilities,
researchers, physicians and advanced practice providers.
President / Chief Medical Officer, ProMedica Physicians 2014-Present
Appointed to lead 800 providers comprised of physicians, specialists and advance practitioners with direct
oversight of strategic planning, business operations, marketing, network development, expansion, new partner
development, recruiting and staff development. Practice support, physician recruitment and primary care physician
contracts, quality care standards, productivity targets, efficiency and quality process improvements, patient
satisfaction goals, accessibility to care standards, and performance targets.
 Developed strategic plan to open urgent care centers within Toledo ensuring ample access to care with
options to accommodate patient needs from office visit through emergency care and in-between
 Employed an Institute Model to develop and maintain Institutes in the following specialties: Orthopedics,
Heart and Vascular, Oncology and Urology resulting in improved quality of patient care and staff
performance.
 Streamlined and standardized physician contracts and compensation utilizing a unified model
incorporating quality performance and incentives parameters.
 Oversaw the opening of a 250,000K sq. ft. Health and Wellness Center that is home to 160 physicians.
Services include Primary Care, Specialists laboratory, radiology and urgent care.
 Developed and implemented a replicable Corporate Health and Wellness model that encompasses full
management of a corporate facility and staff (physicians, nurses, services) and employee programs offered
a la carte including health and wellness and prevention. A model which aims to reduce corporate
healthcare costs and improve employee wellness
Cardiologist (Interventional, Invasive, non-invasive) 2000-Present
Provide patient care specializing in interventional, invasive and non-invasive treatments for finding and preventing
diseases of the heart and blood vessels.
NORTHWEST OHIO CARDIOLOGY CONSULTANTS, Perrysburg, OH 2012-Present

2. DANIEL KENT CASSAVAR
PAGE 2
CARDIOCARE CONSULTANTS, Perrysburg, OH 2003-2012
Founder/Cardiologist (Interventional, Invasive, Non-Invasive)
Developed a thriving practice with 5 physicians providing cardiac care. Oversaw physicians, operations, protocols,
and a staff of 12. Provided cardiac care to patients and performed interventional procedures.
 Designed and developed office layout, processes and procedures to ensure protocols were adhered to and
all patients received quality care.
 Expanded practice and relocated to two additional satellite offices.
 Implemented process improvements that added value and quality improvement which translated into the
significant improvement in patient care and delivery
HEART SPECIALISTS OF NWO, INC., Toledo, OH 1995-2003
Cardiologist (Interventional, Invasive, Non-Invasive)
Recruited to expand existing physician practice that includes 25 physicians specializing in interventional, invasive
and non-invasive treatments for finding and preventing diseases of the heart and blood vessels.
THE TOLEDO HOSPITAL, Toledo, OH 2003-2010
Director Cardiac Catheterization Laboratory
Managed 6 laboratories with a team of 50 including: laboratory technicians, Radiology technicians, nurses and
assistants performing cardiac catheterizations interventional procedures. Oversight of 40 physicians encompassing
case review, peer review, protocol and compliance to attain and maintain CMS and JACHO certifications, as well
as ACC appropriate use criteria utilization
 Improved quality of patient care by developing and implementing pre-operative administrative procedures
and incentivizing technicians that expedited through put and direct patient care.
 Enhance patient safety through training programs, the implementation of a checks and balances process
and conducting peer reviews.
 Improved quality of care by funding on-going technician training and tracking outcomes to achieve
targeted objectives.
 Created open lines of communication for all levels of staff and identified and counseled low performing
personnel to ensure quality and develop talent.
ST. VINCENT MERCY MEDICAL CENTER, Toledo, OH
Director Cardiac Catheterization Laboratory, Division of Cardiology 2001-2003
Director of Invasive Services, Division of Cardiology 2001-2003
Managed a lab with a team of 45 individuals and 50 Physicians
 Developed an outpatient catheterization laboratory on hospital campus jointly owned by physicians.
Director, Emergency Room Chest Pain Center 1997-2000
Initiated the development and implementation of and accredited Chest Pain Center housed in the Emergency
Room that offered early assessment of potential cardiac issues which improved patient care and reduced
unnecessary admissions.
Director, Congestive Heart Failure Center 2001-2003
Initiated and developed a new program, CHF Clinic, which decreased re-admits, improve patient quality of care
and improved patient follow up after discharge.
MEDICAL COLLEGE OF OHIO, Toledo, OH
Clinical Assistant Professor of Medicine 1995-Present
Department of Internal Medicine, Division of Cardiology
OHIO UNIVERSITY COLLEGE OF OSTEOPATHIC MEDICINE, Athens, OH

3. DANIEL KENT CASSAVAR
PAGE 3
Adjunct Clinical Faculty 1995-Present
Department of Internal Medicine
MEDICAL COLLEGE OF OHIO, Toledo, OH
Preceptor Department of Physician Assistant Studies 1999-Present
Voted Preceptor of the Year, 01/2006
EDUCATION & TRAINING
UNIVERSITY OF MICHIGAN, ROSS SCHOOL OF BUSINESS Ann Arbor, MI
Master of Business Administration, 2015
• Strategy Consultant – $2.5B Physician-owned medical insurance company
Charted a roadmap for business evolution into new market segments valued at
$545M as part of a 3-month university-sponsored consulting project. The
project and presentation resulted in a parent-company investment of $15M for
expansion
PROVIDENCE HOSPITAL AND MEDICAL CENTERS
Chief Fellow, Cardiovascular Medicine, 1994-1995
Fellow, Cardiovascular Medicine, 1992-1995
Southfield, MI
ST. MARY MEDICAL CENTER OF UCLA,
Resident, Internal Medicine, 1989-1992
Voted Resident of the Year, 1991-1992
Chief Resident , 1991-1992
Long Beach, CA
MEDICAL COLLEGE OF OHIO Toledo, OH
Medical Degree, 1989
National Board of Medical Examiners, Certification, 1989
JOHN CARROLL UNIVERSITY Cleveland, OH
Bachelor of Science, Biology, 1985
BOARD CERTIFICATIONS
• American Board of Internal Medicine – Subspecialty Interventional Cardiology 2000
• American Board of Internal Medicine – Subspecialty Cardiovascular Diseases 1994
• American Board of Internal Medicine 1992
LICENSURE
• State of Michigan 1992
• State of Ohio 1992
• State of California 1989

4. DANIEL KENT CASSAVAR
PAGE 4
HOSPITAL PRIVILEGES
• ProMedica Bay Park Community Hospital, Oregon, OH
• ProMedica Bixby Hospital, Adrian, MI
• ProMedica Defiance Regional Hospital, Defiance, OH
• ProMedica Flower Hospital, Sylvania, OH
• ProMedica Fostoria Community Hospital, Fostoria, OH
• ProMedica Herrick Hospital, Tecumseh, MI
• ProMedica Monroe Regional Hospital, Monroe, MI
• ProMedica Toledo Hospital, Toledo, OH
• ProMedica Wildwood Orthopaedic and Spine Hospital, Toledo, OH
• St. Vincent Mercy Medical Center, Toledo, OH
• Mercy St. Anne Hospital, Toledo, OH
• Mercy St. Charles Hospital, Toledo, OH
• St. Luke’s Hospital, Maumee, OH
PROFESSIONAL SOCIETIES AND ORGANIZATIONS
• American Medical Association
• American College of Physicians, Fellow
• American College of Cardiology, Fellow
• American College of Cardiology Toledo and Michigan Chapters
• American Heart Association
• American College of Chest Physicians
• The Society of Vascular Medicine and Biology
• Medical College of Ohio, Toledo, OH
• St. Charles Mercy Hospital, Oregon, OH
• St. Luke’s Hospital, Maumee, OH
• St. Anne Mercy Hospital, Toledo, OH
• Wood County Hospital, Bowling Green, OH
• Defiance Regional Medical Center, Defiance, OH
• Bixby Medical Center, Adrian, MI
• Herrick Memorial Hospital, Tecumseh, MI
• Fostoria Community Hospital, Fostoria, OH
• Defiance Regional Medical Center Board, Defiance, Ohio

5. DANIEL KENT CASSAVAR
PAGE 5
ADDENDUM
PUBLICATIONS
Congestive Heart Failure, in Hospital Physician Board Review in Cardiology, edited by Jeffrey M. Zaks, M.D., July 1994.
Noninvasive Methods in Cardiology, in Hospital Physician Board Review in Cardiology, edited by Jeffrey M. Zaks, M.D.,
(in press).
Valvular Heart Disease, in Hospital Physician Board Review in Cardiology, edited by Jeffrey M. Zaks, M.D., (in press).
ABSTRACTS
Textbook of Nuclear Cardiology, D. Cassavar, L. Goodenday, Computerized learning tool presented at the American
College of Cardiology Annual Meeting, Atlanta, Georgia, March 1994.
Cardiac Sarcoidosis, D. Cassavar, S. David, Oral presentation at the Michigan Chapter of the American College of
Cardiology Annual Meeting, Shanty Creek, Michigan, October 1993.
Cor Triatriatum: A case report and review of the literature, D. Cassavar and I. Grinberg, (submitted).
Cardiac Lipoma of the Intraventricular Septum, D. Cassavar, and J. Crawford, Case report and review of the literature
(submitted to the American College of Chest Physicians).
Accuracy of Central Venous Pressure Measurement from the Femoral Vein, D. Cassavar, A. Karamali, J. Kanukunta, and S.
David, Poster presentation at the Michigan Chapter of the American College of Cardiology Annual Meeting,
Traverse City, Michigan, October 1994.
Calcific Pericarditis, S. Pakbaz, D. Cassavar, A. Karamali, and H. Lee, Poster presentation at the Michigan Chapter of
the American College of Physicians Annual Meeting, Traverse City, Michigan, September 1994.
Asystole and Irreversible Pacemaker Failure during Electrocautery Pacemaker Dependency, D. Cassavar, M. Moran, and H.
Green, Case and review of the literature (submitted to Pace, March 1995).
Differences Between Young Women and Young Men in Risk Factors for Acute Myocardial Infarction, T. Hafford, A. Karamali,
D. Cassavar, M. Moran, and D.Cunningham, Presented at the Resident Research Day Program, Providence
Hospital, April 1995.
Echocardiographic Diagnosis of the Contracted Form of Endocardial Fibroelastosis, J. Kunukunta, A. Karamali, D. Cassavar
and R. Miller, (submitted to Chest 1995).

6. DANIEL KENT CASSAVAR
PAGE 6
CLINICAL TRIALS AND RESEARCH STUDIES
CHESS (Comparative HDL Efficacy and Safety Study) A Multi-center,
Double-blind, Randomized, Parallel, 28-Week Study to Evaluate the
Efficacy and Safety of Simvastatin 80 mg/day Versus Atorvastatin 80 mg/day in
patients with Hypercholesterolemia
SWORD Survival With ORal D-sotalol. Evaluation of the effect of sotalol - a non-selective
beta-blocker and potassium channel blocker (a class III anti-arrhythmic) therapy on
the morbidity and mortality in patients with CHF.
CLINICAL TRIALS AND RESEARCH STUDIES (Con’t.):
MATE Medicine versus Angiography in the Triage of Unstable Angina/Non-ST Elevation
Myocardial Infarction.
GUSTO I & II Global Utilization of Streptokinase and Tissue Plasminogen Activator (t-PA) for
Occluded Coronary Arteries.
AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management sponsored by the
National Heart, Lung, and Blood Institute.
GUSTO IV ACS A Phase III, randomized, double-blind, placebo-controlled trial evaluating the
efficacy and safety of ReoPro, given as a bolus followed by a 24 or 48 hour infusion,
for the treatment of acute coronary syndrome without ST segment elevation.
AMISTAD II A randomized, double-blind, placebo-controlled, multi-center trial to evaluate the
efficacy and safety of Adenosine (Pallcor â, Adenosine Injection) as an adjunct to
Reperfusion therapy (thrombolysis or mechanical reperfusion) in the treatment of
acute anterolateral myocardial infarction.
VALIANT (Valsartan in Acute Myocardial Infarction) A multi-national, multi-center,
double-blind, randomized, active-controlled, parallel group study comparing the
efficacy and safety of long-term treatment with Valsartan, Captopril, and Their
Combination in high-risk patients after myocardial infarction
ESPRIT Enhanced Suppression of Platelet Receptor GP IIb-IIIa using INTEGRILIN
Therapy.
CURE Effects of Clopidogrel in addition to aspirin in patients with acute coronary
syndromes without ST-segment elevation.
ACUITY A randomized comparison of Angiomax (bivalirudin) versus heparin (unfractionated
heparin or enoxaparin) in patients undergoing early invasive management for acute
coronary syndromes without ST-segment elevation.
TRITON TIMI-38 A comparison of (CS-747) and Clopidogrel in acute coronary syndrome subjects who
are to undergo percutaneous coronary intervention.
LUNAR A prospective, randomized, open-label, three-arm, parallel group, 12-week study to

7. DANIEL KENT CASSAVAR
PAGE 7
compare the efficacy of rosuvastatin 20 mg and 40 mg with atorvastatin 80 mg in
lowering LDL-C over 6-12 weeks of once daily therapy.
IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) A
multicenter, double blind, randomized study to establish the clinical benefit and
safety of Vytorin (ezetimibe/Simvastatin tablet) vs. Simvastatin monotherapy in
high-risk subjects presenting with acute coronary syndrome (ACS).
CHAMPION PCI A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects who require
percutaneous coronary intervention.
CLINICAL TRIALS AND RESEARCH STUDIES (Con’t.):
CHAMPION Platform Cangrelor versus standard therapy to achieve optimal management of platelet
inhibition – A clinical trial comparing treatment with Cangrelor (in combination with
usual care, in subjects who require percutaneous coronary intervention).
TRILOGY ACS A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS)
subjects with unstable angina/non-ST-elevation myocardial infarction
(UA/NSTEMI) who are medically managed.
XIENCE V USA Everolimus Eluting Coronary Stent System USA Post approval study to evaluate
patient compliance with adjunctive antiplatelet therapy and major bleeding
complications, and to determine clinical device and procedural success during
commercial use.
AXIOM/ACS A Phase 2, double blind, randomized, placebo-controlled study of the safety and
efficacy of TAK-442 in subjects with acute coronary syndromes.
P-SELECT ACS A multi-center, randomized, double-blind, placebo-controlled study evaluating the
efficacy and safety of 2 doses of RO4905417 (R1512) administered to patients with
non ST-elevation infarction (Non-STEMI) undergoing percutaneous coronary
intervention (PCI).
PEGASUS A randomized, double blind, placebo controlled, parallel group, multinational trial, to
assess the prevention of thrombotic events with Ticagrelor compared to placebo on
a background of Acetyl Salicylic Acid (ASA) therapy in patients with a history of
myocardial infarction.
EVITA Evaluation of Varenicline (Champix™) in SmokIng Cessation of PaTients post-
Acute coronary syndrome (EVITA) Trial.
CADENCE 215 A multi-center, parallel-group, double-blind, placebo-controlled, randomized,
ascending dose trial to determine the safety, tolerability, pharmacokinetics and
efficacy and intravenous infusions of OPC-108459 administered to subjects with
paroxysmal and persistent atrial fibrillation.
ABSORB III A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable
Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery

8. DANIEL KENT CASSAVAR
PAGE 8
Lesions.
MASTER II MGuard™ Prime Micronet Covered Coronary Stent System is a cobalt chromium
(Co-Cr, L-605 alloy) stent, with a polyethylene terephthalate (PET) mesh covering,
mounted on a rapid exchange (RX) delivery system.